title: Factors associated with spontaneous release of vitreomacular traction.
abstract: OBJECTIVE
  To analyze the factors that may predict the release of vitreomacular traction (VMT) and vitreomacular adhesion.
  
  
  METHODS
  Retrospective case-control study of sixty-one patients with VMT imaged by optical coherence tomography over at least 3 months. Records from all patients seen at the University of Iowa from January 2012 to September 2013 were screened for the ICD9 code for VMT, vitreomacular adhesion, and epiretinal membrane (379.27 and 362.56). Release of VMT (R-VMT) was defined by resolution of patients' symptoms or traction by optical coherence tomography without surgical intervention or ocriplasmin injection. Individual factors or characteristics were evaluated by chi-square test. Using a binary logistic regression model, the potentially prognostic factors were evaluated for contribution to R-VMT.
  
  
  RESULTS
  Of the 61 patients that met entry criteria, 21 (35%) developed R-VMT during optical coherence tomography follow-up, and 40 (65%) did not. Isolated inner retinal distortion without outer retinal involvement was significantly associated with R-VMT (P = 0.01). Vitreous injections were also associated with R-VMT (P = 0.02).
  
  
  CONCLUSIONS
  Eyes with VMT and isolated inner retinal distortion and those receiving vitreous injections are more likely to develop VMT release without the need for surgical intervention or ocriplasmin treatment.
authors.affiliation: *Vitreoretinal Service, Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinics, Iowa City, Iowa; and †Department of Ophthalmology, Queen's University, Hotel Dieu Hospital, Kingston, Canada.
authors.forename: David R P
authors.initials: DR
authors.lastname: Almeida
authors.forename: Eric K
authors.initials: EK
authors.lastname: Chin
authors.forename: Karim
authors.initials: K
authors.lastname: Rahim
authors.forename: James C
authors.initials: JC
authors.lastname: Folk
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Russell
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D016022:Case-Control Studies; D005128:Eye Diseases / Q000175:diagnosis / Q000503:physiopathology*; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008266:Macula Lutea / Q000503:physiopathology*; D008268:Macular Degeneration / Q000188:drug therapy; D008297:Male; D012075:Remission, Spontaneous; D012164:Retinal Diseases / Q000175:diagnosis / Q000503:physiopathology*; D012189:Retrospective Studies; D000267:Tissue Adhesions / Q000175:diagnosis / Q000503:physiopathology; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014821:Vitrectomy; D014822:Vitreous Body / Q000503:physiopathology*
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A